iMA203 is a TCR-T cell developed by IMMatics' proprietary ActenGine platform and targets the melanoma antigen PRAME presented by HLA-A*02.
The Zhitong Finance App learned that Immatics (IMTX.US) announced the latest data on its development of T-cell receptor T-cell (TCR-T) therapy IMA203 to treat patients with metastatic melanoma in its financial report for the first quarter of 2024. The analysis showed that 87% of patients achieved tumor reduction, and the confirmed objective response rate (CoRR) of patients reached 55%. Immatics plans to provide the next clinical data update for IMA203 at the medical conference in the second half of 2024. At the same time, the company also plans to launch a registered phase 2/3 clinical trial of IMA203 as a second-line treatment for melanoma patients this year after further discussions with the US FDA.
iMA203 is a TCR-T cell developed by Immatics' proprietary ActenGine platform and targets the melanoma antigen PRAME presented by HLA-A*02. ActEngine is an individualized cell therapy platform for patients with advanced solid tumors.